A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients With Moderate to Severe COPD, Compared With Foradil Aerolizer (12 and 24 microg Open-Label) as Active Controls.

Trial Profile

A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients With Moderate to Severe COPD, Compared With Foradil Aerolizer (12 and 24 microg Open-Label) as Active Controls.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2012

At a glance

  • Drugs Formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2011 Actual end date (Jul 20101 added as reported by ClinicalTrials.gov.
    • 16 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jul 2011 Planned End Date changed from 1 Feb 2012 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top